The impact of atherosclerotic renovascular disease on diabetic renal failure

Atherosclerotic renovascular disease (ARVD) is common in the general population, and its prevalence increases with age. Parallel studies show it is also common in patients with diabetes. The widespread use of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists for heart and kidney disease might therefore expose arteriopathic diabetic patients to potential harm if they had critical renal artery stenosis. This review looks at the natural history of ARVD in the diabetic and non-diabetic populations: while it is common, it only rarely leads to renal failure. Hence intervention to revascularize ischaemic kidneys on the basis of radiological appearances alone may subject some patients to unnecessary therapy. Although untested by randomized trial, a policy of watchful waiting may be the simplest strategy for most diabetic patients with suspected ARVD, reserving angiography and angioplasty (usually backed up by a stent) for those with an abrupt decline in renal function and no other cause for renal deterioration. Future clinical trials may better define subgroups of patients who will truly benefit from renal revascularization.